Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Emergent BioSolutions Q4 2023 Adj EPS $(0.770) Misses $(0.190) Estimate, Sales $276.600M Miss $293.533M Estimate

Author: Benzinga Newsdesk | March 06, 2024 05:19pm
Emergent BioSolutions (NYSE:EBS) reported quarterly losses of $(0.770) per share which missed the analyst consensus estimate of $(0.190) by 305.26 percent. The company reported quarterly sales of $276.600 million which missed the analyst consensus estimate of $293.533 million by 5.77 percent. This is a 16.36 percent decrease over sales of $330.700 million the same period last year.

Posted In: EBS


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist